This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of these benzodiazepine derivatives and methods of using these derivatives or compositions in the treatment of cognitive impairment associated with central nervous system (snc) disorders. in particular, it relates to the use of an a5-containing gabaa receptor agonist (for example, an a5-containing gabaa receptor positive allosteric modulator), as described herein, in the treatment of cognitive impairment associated with central nervous system disorders ( snc) in an individual who needs or is at risk, including, without limitation, individuals at or at risk of developing age-related cognitive impairment, mild cognitive impairment (ccl), amnestic ccla (ccla), age-associated memory impairment ( (cmai), age-related cognitive decline (dcri), dementia, alzheimer's (da), prodromal disease, posttraumatic stress disorder (tept), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (she), cognitive impairment cancer therapy, mental retardation, parkinson's disease (dp), autistic spectrum disorders, fragile x syndrome, rett syndrome, behavior compulsive and chemical addiction. also refers to the use of an Î ± 5-containing gabaa receptor agonist (e.g., a Î ± 5-containing gabaa receptor positive allosteric modulator), as described herein, in the treatment of brain cancers (including brain tumors, e.g., medulloblastomas) and the cognitive impairment associated with them.esta invenção refere-se a derivados de benzodiazepina, composições compreendendo quantidades terapeuticamente eficazes destes derivados de benzodiazepina e métodos de uso destes derivados ou composições no tratamento do comprometimento cognitivo associado aos distúrbios do sistema nervoso central (snc). em particular, refere-se ao uso de um agonista do receptor gabaa contendo a5 (por exemplo, um modulador alostérico positivo para o receptor gabaa contendo a5), conforme descrito neste documento,
